Information Provided By: 
Fly News Breaks for December 17, 2015
MYL
Dec 17, 2015 | 06:36 EDT
Goldman analyst Jami Rubin added Mylan to the Conviction Buy List and raised earnings estimates on EpiPen dynamics and sees upside to shares. Rubin sees upside in EpiPen starting in Q4 given the recent recall of Sanofi's Auvi-Q, believes management to focus on shareholder value creation, expects Mylan to file generic Advair this month which could generate $300M-$500M in sales annually, and said the company's leverage ratio is relatively low.
News For MYL From the Last 2 Days
There are no results for your query MYL
